Orally available small molecule
Safusidenib Clin2 glioma, Clin1 cholangiocarcinoma, Clin1 solid tumors; AB-329 2 trials Clin1 NSCLC, Clin1 solid tumors; 5+ undisclosed programs Clin0 undisclosed
AnHeart Therapeutics is developing novel precision oncology therapeutics for areas of unmet clinical need. AnHeart’s lead candidate, taletrectinib, is currently in Phase 2 trials in a subset of patients with non-small cell lung cancer (NSCLC). Taletrectinib inhibits the protein ROS1, which is mutated in ~2% of NSCLC patients and several other cancers. While first generation ROS1 inhibitors exist, there are patients who are resistant to treatment due to treatment-resistant mutations. AnHeart developed Taletrectinib to show potency against resistance tumors and has so far shown a strong safety profile and can pass the blood brain barrier with potential to address brain metastasis. AnHeart is also advancing many other precision oncology clinical programs.